Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Multigene MRD Assessment Improves AML Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

Matthew P. Mulé, BS, Gabriel N. Mannis, MD, Jerald P. Radich, MD, Brent L. Wood, MDPhD, Nestor R. Ramos, MD, Catherine E. Lai, MD, Michael Flanders, BA, Charalambos Andreadis, MD MSCE, Lloyd E. Damon, MD, Aaron C. Logan, MDPhD, Thomas G. Martin, MD, Christopher S. Hourigan, MDPhD

Blood (2015) 126 (23): 4350.

https://doi.org/10.1182/blood.V126.23.4350.4350

Published: 2015

Journal Articles

KIR and HLA Genotypes Influence Clinical Outcome in Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in Combination with Lenalidomide and Dexamethasone

John Marra, BS, Juan Du, MD PhD, Jimmy Hwang, PhD, Jeffrey L Wolf, MD, Thomas G. Martin, MD, Jeffrey M Venstrom, MD

Blood (2014) 124 (21): 2126.

https://doi.org/10.1182/blood.V124.21.2126.2126

Published: 2014

Journal Articles

Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)

David S. Siegel, MD PhD, Jesus G. Berdeja, MD, Jeffrey R. Infante, MD, Jonathan L. Kaufman, MD, Michael (Luhua) Wang, MD, Thomas G. Martin, MD, Ruben Niesvizky, MD, Frederic J. Reu, MD, Sundar Jagannath, MD, Kanya Rajangam, MDPhD, Mei Huang, MS, Ravi Vij, MD

Blood (2014) 124 (21): 2134.

https://doi.org/10.1182/blood.V124.21.2134.2134

Published: 2014

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Rachid Baz, MD, Thomas G. Martin, MD, Melissa Alsina, MD, Kenneth H. Shain, MD PhD, Hearn J. Cho, MD PhD, Jeffrey L Wolf, MD, Anuj Mahindra, MD, Ajai Chari, MD, Daniel M Sullivan, MD, Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Xiuhua Zhao, Hui-Yi Lin, PhD, Sundar Jagannath, MD

Blood (2014) 124 (21): 303.

https://doi.org/10.1182/blood.V124.21.303.303

Published: 2014

Journal Articles

Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma

Blood (2014) 124 (21): 4701.

https://doi.org/10.1182/blood.V124.21.4701.4701

Published: 2014

Journal Articles

A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Thomas G. Martin, MD, Rachid Baz, MD, Don M. Benson, MD PhD, Nikoletta Lendvai, MD PhD, Frank Campana, MD, Eric Charpentier, Ravi Vij, MBBS, MD

Blood (2014) 124 (21): 83.

https://doi.org/10.1182/blood.V124.21.83.83

Published: 2014

Journal Articles

A Phase I/II Study of Xcellerated T Cells ™ after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

David Siegel, MD, Ravi Vij, MD, Robert A. Vescio, MD, Ivan M. Borrello, MD, Thomas G. Martin, MD, James R. Berenson, MD, Christophe Ferrand, PhD, Fatimit Janmohamed, Ronald J. Berenson, MD, Mark W. Frohlich, MD

Blood (2004) 104 (11): 925.

https://doi.org/10.1182/blood.V104.11.925.925

Published: 2004

NARROW

Multigene MRD Assessment Improves AML Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

KIR and HLA Genotypes Influence Clinical Outcome in Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in Combination with Lenalidomide and Dexamethasone

Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma

A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

A Phase I/II Study of Xcellerated T Cells ™ after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Multigene MRD Assessment Improves AML Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

KIR and HLA Genotypes Influence Clinical Outcome in Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in Combination with Lenalidomide and Dexamethasone

Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma

A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

A Phase I/II Study of Xcellerated T Cells ™ after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only